Medical technology company Vibrosense Dynamics has received a so-called Intention to Grant from the European Patent Office, EPO. This concerns a biomarker that is intended to be able to predict the risk of nerve damage during chemotherapy treatment. This is stated in a press release.The biomarker aims to identify patients with an increased risk of chemotherapy-induced peripheral neuropathy, which may enable more individualized treatment.The patent covers both method and apparatus and strengthens the company's intellectual property protection.Intention to Grant means that the patent has not yet been formally granted, but EPO has announced that it intends to grant the patent after certain formal steps.